Prostate-Specific Antigen
-
Subject Areas on Research
-
A 66-year-old man with prostate-specific antigen recurrence and lung mass after radical prostatectomy.
-
A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI).
-
A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group.
-
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
-
A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer.
-
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
-
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
-
A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
-
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
-
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
-
A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer.
-
A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
-
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
-
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
-
A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]).
-
A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone.
-
A structured literature review to determine the use of the American Society for Therapeutic Radiology and Oncology consensus definition of biochemical failure.
-
ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer.
-
ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging.
-
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
-
Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
-
Active surveillance as a treatment option for prostate cancer.
-
Active surveillance for African-American men with prostate cancer: of course! Pro.
-
Active surveillance for early-stage prostate cancer: review of the current literature.
-
Active surveillance for intermediate-risk prostate cancer in African American and non-Hispanic White men.
-
Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era?
-
Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer.
-
Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method.
-
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
-
Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.
-
Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease.
-
Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines.
-
Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
-
Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update.
-
Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death.
-
Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
-
Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted?
-
African American Men With Low-Risk Prostate Cancer Are Candidates for Active Surveillance: The Will-Rogers Effect?
-
African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance.
-
After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
-
Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
-
Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men.
-
Age-specific reference ranges for serum prostate-specific antigen in black men.
-
Agent Orange and long-term outcomes after radical prostatectomy.
-
Aggressive prostate cancer masquerading as acute prostatitis.
-
Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.
-
American Society of Clinical Oncology 2013 top five list in oncology.
-
An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time.
-
Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.
-
Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multi-parametric magnetic resonance imaging.
-
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
-
Apical soft tissue biopsies predict biochemical failure in radical perineal prostatectomy patients with apical cancer involvement.
-
Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study.
-
Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer-Reply.
-
Assessment after focal therapy: what is the latest?
-
Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer.
-
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
-
Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer.
-
Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database.
-
Association of Obesity-Related Hemodilution of Prostate-Specific Antigen, Dihydrotestosterone, and Testosterone.
-
Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.
-
Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
-
Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults.
-
Association of cigarette smoking with interval to biochemical recurrence after radical prostatectomy: results from the SEARCH database.
-
Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate.
-
Associations among statins, preventive care, and prostate cancer mortality.
-
Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor.
-
Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.
-
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.
-
Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience.
-
Baseline prostate-specific antigen testing at a young age.
-
Benign prostatic hyperplasia. New concepts in the 1990s.
-
Best screening tests for prostate cancer.
-
Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer.
-
Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer.
-
Biochemical recurrence of prostate cancer.
-
Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
-
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.
-
Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer.
-
Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight.
-
Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer.
-
Body composition and serum prostate-specific antigen: review and findings from Flint Men's Health Study.
-
Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
-
Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.
-
Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study.
-
CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.
-
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
-
Cadmium-induced neoplastic transformation of human prostate epithelial cells.
-
Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer?
-
Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?
-
Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience.
-
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.
-
Capromab Pendetide imaging of prostate cancer.
-
Cell-specific aptamers for targeted therapies.
-
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.
-
Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era.
-
Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences.
-
Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy.
-
Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database.
-
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.
-
Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer.
-
Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
-
Clinical Trial Protocol for a Randomized Trial of Community Health Worker-led Decision Coaching to Promote Shared Decision-making on Prostate Cancer Screening Among Black Male Patients and Their Providers.
-
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.
-
Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation.
-
Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.
-
Clinical characteristics of African-American men with hereditary prostate cancer: the AAHPC Study.
-
Clinical endpoints for drug development in prostate cancer.
-
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
-
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer.
-
Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
-
Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
-
Clinically relevant changes in family history of cancer over time.
-
Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
-
Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.
-
Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate.
-
Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
-
Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
-
Comments on: High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localize prostate cancer: toxicity and 6-years biochemical results.
-
Common variation in the BRCA1 gene and prostate cancer risk.
-
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
-
Comparison of DRE and PSA in the Detection of Prostate Cancer.
-
Comparison of Outcomes Between Preoperatively Potent Men Treated with Focal Versus Whole Gland Cryotherapy in a Matched Population.
-
Comparison of ante- and post-mortem PSA levels for epidemiological studies.
-
Comparison of fresh frozen serum to proficiency testing material in College of American Pathologists surveys: alpha-fetoprotein, carcinoembryonic antigen, human chorionic gonadotropin, and prostate-specific antigen.
-
Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy.
-
Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis.
-
Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
-
Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T.
-
Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 NG/ML.
-
Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment.
-
Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry.
-
Cost implications of PSA screening differ by age.
-
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
-
Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families.
-
Defining low-value PSA testing in a large retrospective cohort: Finding common ground between discordant guidelines.
-
Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?
-
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
-
Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.
-
Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.
-
Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System.
-
Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy.
-
Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy.
-
Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy.
-
Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients.
-
Dietary inflammatory index (DII) and risk of prostate cancer in a case-control study among Black and White US Veteran men.
-
Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.
-
Do Hispanic Men Have Worse Outcomes After Radical Prostatectomy? Results From SEARCH.
-
Do the current subclassifications of stage T3 adenocarcinoma of the prostate have clinical relevance?
-
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
-
Docetaxel for advanced prostate cancer: how early to start?
-
Does Any Racial Disparity Exist in Oncologic Outcomes After Primary Cryotherapy for Prostate Cancer? A Matched-pair Comparative Analysis of the Cryo On-Line Data Registry.
-
Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
-
Does Obesity Modify the Ability of Prebiopsy Prostate Specific Antigen to Detect Prostate Cancer on Repeat Biopsy? Results from the REDUCE Study.
-
Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE.
-
Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?
-
Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database.
-
Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy?
-
Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
-
Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
-
Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?
-
Dosimetry and cancer control after low-dose-rate prostate brachytherapy.
-
Drug development in prostate cancer: time to embrace RECIST?
-
Dynamic prediction of metastases after radical prostatectomy for prostate cancer.
-
Early prostate cancer: prevention, treatment modalities, and quality of life issues.
-
Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation.
-
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
-
Editorial Comment.
-
Editorial Comment.
-
Editorial Comment.
-
Editorial Comment.
-
Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
-
Editorial comment.
-
Editorial comment. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--Implications for a risk-adapted follow-up strategy.
-
Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy.
-
Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research.
-
Effect of flexible cystoscopy on serum prostate-specific antigen values.
-
Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research.
-
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302.
-
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
-
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.
-
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
-
Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
-
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
-
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
-
Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer.
-
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
-
Epidemiology and screening for prostate cancer.
-
Equivalent uniform dose, D(90), and V(100) correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer.
-
Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer.
-
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.
-
Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.
-
Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer.
-
Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.
-
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
-
Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy.
-
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
-
External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: results from the Duke Prostate Center Database.
-
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
-
Factors associated with appropriate and low-value PSA testing.
-
Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database.
-
Factors predicting prostatic biopsy Gleason sum under grading.
-
Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.
-
Family history of prostate cancer and relapse after definitive external beam radiation therapy.
-
Fasting times in serum PSA assay.
-
Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience.
-
Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.
-
First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database.
-
Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen.
-
Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
-
Focal cryotherapy for prostate cancer.
-
Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria.
-
Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting.
-
Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy.
-
Gene therapy for prostate cancer: where are we now?
-
Genetically Informed Prostate Cancer Screening.
-
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
-
Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.
-
Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer.
-
Guideline for the management of clinically localized prostate cancer: 2007 update.
-
Hierarchical Bayesian mixture modelling for antigen-specific T-cell subtyping in combinatorially encoded flow cytometry studies.
-
High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
-
Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.
-
Highlights in advanced prostate cancer from the 2014 AUA and ASCO meetings.
-
Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy.
-
Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
-
Hormone naïve prostate cancer: predicting and maximizing response intervals.
-
How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care.
-
Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro.
-
Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy.
-
Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
-
Immunohistochemical characterization of neuroendocrine cells in prostate cancer.
-
Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen.
-
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
-
Immunoreactive prostatic specific antigen in male periurethral glands.
-
Impact of Low Carbohydrate Diet on Self-Report Fatigue and Weakness in Prostate Cancer Patients.
-
Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.
-
Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.
-
Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers.
-
Impact of radical prostatectomy in the management of clinically localized disease.
-
Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system.
-
Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network.
-
Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing.
-
Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma.
-
In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
-
In regard to Lee et al.: "Dosimetry and cancer control after low-dose-rate prostate brachytherapy" (Int J Radiat Oncol Biol Phys 2005;61:52-59).
-
In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer.
-
Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
-
Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA.
-
Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen.
-
Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy.
-
Informed consent. From bodily invasion to the seemingly mundane.
-
Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
-
Initial outcomes and insights from a novel high-risk prostate cancer screening clinic.
-
Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.
-
Initiation of salvage therapy for prostate cancer.
-
Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival.
-
Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
-
Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.
-
Investigation momentum: the relentless pursuit to resolve uncertainty.
-
Is PSA related to serum cholesterol and does the relationship differ between black and white men?
-
Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
-
Is prostate cancer stage migration continuing for black men in the PSA era?
-
Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy.
-
Is the PSA test useless?
-
Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.
-
Ligation of prostate cancer cell surface GRP78 activates a proproliferative and antiapoptotic feedback loop: a role for secreted prostate-specific antigen.
-
Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis.
-
Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues.
-
Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy.
-
Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy.
-
Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis.
-
Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.
-
Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL.
-
Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05).
-
Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
-
Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
-
Low-risk prostate cancer patient: active treatment.
-
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
-
Management of the patient with a rising PSA alone.
-
Massive locally extensive prostate cancer.
-
Medical technologies for the diagnosis of prostate cancer.
-
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
-
Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer.
-
Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.
-
Metformin use and risk of prostate cancer: results from the REDUCE study.
-
Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.
-
Molecular implications of the antiandrogen withdrawal syndrome.
-
Molecular markers in prostate cancer: the role in preoperative staging.
-
Monocyte counts and prostate cancer outcomes in white and black men: results from the SEARCH database.
-
Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer.
-
Most Gleason 8 Biopsies are Downgraded at Prostatectomy-Does 4 + 4 = 7?
-
Most of patients with localized prostate cancer will be treated in the future? | Opinion: No.
-
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
-
Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
-
Multivariate models as predictors of pathological stage using Gleason score, clinical stage, and serum prostate-specific antigen.
-
NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy.
-
NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
-
NCCN clinical practice guidelines in oncology: prostate cancer.
-
Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy.
-
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
-
Neoadjuvant hormone therapy: the Canadian trials.
-
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
-
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
-
Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging: proof of principle and initial clinical experience with extraprostatic extension.
-
Novel therapies are changing treatment paradigms in metastatic prostate cancer.
-
Null association between vitamin D and PSA levels among black men in a vitamin D supplementation trial.
-
Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans.
-
Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
-
Obesity and survival after radical prostatectomy: A 10-year prospective cohort study.
-
Obesity, race, and long-term prostate cancer outcomes.
-
Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.
-
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
-
Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy.
-
On model specification and selection of the Cox proportional hazards model.
-
Oncological and functional outcomes of men undergoing primary whole gland cryoablation of the prostate: A 20-year experience.
-
Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study.
-
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.
-
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
-
PC3 is a cell line characteristic of prostatic small cell carcinoma.
-
PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study.
-
PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium.
-
PSA thresholds for prostate cancer detection.
-
PSCA polymorphisms and gastric cancer susceptibility in an eastern Chinese population.
-
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.
-
Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.
-
Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.
-
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.
-
Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer.
-
Patient-physician communication about early stage prostate cancer: analysis of overall visit structure.
-
Patterns of Prostate-Specific Antigen Testing and Prostate Biopsies During the COVID-19 Pandemic.
-
Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment.
-
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
-
Percent tumor involvement and risk of biochemical progression after radical prostatectomy.
-
Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer.
-
Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion.
-
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
-
Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer.
-
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.
-
Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.
-
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
-
Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy.
-
Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.
-
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
-
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.
-
Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.
-
Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.
-
Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate.
-
Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.
-
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.
-
Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917.
-
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
-
Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
-
Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features.
-
Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen.
-
Platinum sensitivity in metastatic prostate cancer: does histology matter?
-
Polymorphisms in the prostate-specific antigen gene promoter do not predict serum prostate-specific antigen levels in African-American men.
-
Population screening for prostate cancer and emerging concepts for young men.
-
Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.
-
Post-radical prostatectomy management options for positive surgical margins: argument for observation.
-
Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens.
-
Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy.
-
Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.
-
Potential selection bias in a community-based study of PSA levels in African-American men.
-
Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database.
-
Precision Medicine Approaches When Prostate Cancer Akts Up.
-
Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH.
-
Predicting and monitoring results of therapy.
-
Predicting biopsy-proven prostate cancer recurrence following cryosurgery.
-
Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database.
-
Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer.
-
Predicting non-organ-confined prostate cancer in men diagnosed after 2000.
-
Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics.
-
Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors.
-
Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
-
Predicting tumor failure in prostate carcinoma after definitive radiation therapy: limitations of models based on prostate-specific antigen, clinical stage, and Gleason score.
-
Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
-
Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.
-
Predictors of Rectourethral Fistula Formation After Primary Whole-Gland Cryoablation for Prostate Cancer: Results from the Cryo On-Line Database Registry.
-
Predictors of extracapsular extension and positive margins in African American and white men.
-
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
-
Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance.
-
Preoperative predictors of pathologic stage T2a in low-risk prostate cancer: implications for focal therapy.
-
Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy.
-
Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior.
-
Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone.
-
Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.
-
Prevalence and correlates of non-tissue prostate cancer diagnosis in the United States.
-
Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial.
-
Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry.
-
Primary care providers' perspectives on discontinuing prostate cancer screening.
-
Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer.
-
Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center.
-
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
-
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
-
Prognostic indicators in hormone refractory prostate cancer.
-
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
-
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.
-
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583.
-
Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.
-
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.
-
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.
-
Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data.
-
Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA.
-
Prostate Cancer Detection Rate of Freehand versus 3-Dimensional Template Mapping Biopsy Using a Magnetic Resonance Imaging-Ultrasound Fusion Device in Biopsy Naïve Men.
-
Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms.
-
Prostate Cancer Screening for Gay Men in the United States.
-
Prostate MRI in Stereotactic Body Radiation Treatment Planning and Delivery for Localized Prostate Cancer.
-
Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.
-
Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation.
-
Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men.
-
Prostate biopsy quantitative histology as a staging and prognostic factor.
-
Prostate brachytherapy: a descriptive analysis from CaPSURE.
-
Prostate cancer 1997--practicing what we preach.
-
Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum.
-
Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.
-
Prostate cancer early detection practices among men with a family history of disease.
-
Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database.
-
Prostate cancer in the Baby Boomer generation: results from CaPSURE.
-
Prostate cancer in young men: an important clinical entity.
-
Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy.
-
Prostate cancer screening.
-
Prostate cancer screening. Why the controversy?
-
Prostate cancer with solitary parotid metastasis correctly diagnosed with immunohistochemical stains.
-
Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.
-
Prostate cancer.
-
Prostate cancer.
-
Prostate cancer: an evolving paradigm.
-
Prostate cancer: the new landscape.
-
Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay.
-
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study.
-
Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy.
-
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.
-
Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.
-
Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
-
Prostate specific antigen only progression of prostate cancer.
-
Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer.
-
Prostate specific antigen recurrence after definitive therapy.
-
Prostate specific antigen testing in men older than 75 years in the United States.
-
Prostate specific antigen: a decade of discovery--what we have learned and where we are going.
-
Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.
-
Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
-
Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone.
-
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
-
Prostate-specific antigen as a marker of disease activity in prostate cancer.
-
Prostate-specific antigen as a marker of disease activity in prostate cancer.
-
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.
-
Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation.
-
Prostate-specific antigen endpoints in hormone-refractory prostate cancer.
-
Prostate-specific antigen in black men.
-
Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
-
Prostate-specific antigen levels in young white and black men 20 to 45 years old.
-
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
-
Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.
-
Prostate-specific antigen screening among young men in the United States.
-
Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995.
-
Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
-
Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men.
-
Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility.
-
Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer.
-
Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men.
-
Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
-
Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens.
-
Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials.
-
Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches.
-
Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report.
-
Psychosocial trajectories of men monitoring prostate-specific antigen levels following surgery for prostate cancer.
-
Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75.
-
Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.
-
Quantitative expression profile of PSGR in prostate cancer.
-
Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.
-
Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
-
Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer.
-
Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
-
Racial differences in prostate cancer screening by family history.
-
Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients.
-
Radical perineal prostatectomy: a model for evaluating local response of prostate therapy.
-
Radical perineal prostatectomy: oncological outcome during a 20-year period.
-
Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
-
Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.
-
Radical prostatectomy versus observation for localized prostate cancer.
-
Radical prostatectomy versus radiation therapy: can pretreatment nomograms be used to select the appropriate prostate cancer treatment?
-
Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
-
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.
-
Radiotherapy for locally recurrent prostate cancer.
-
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
-
Randomized trial of community health worker-led decision coaching to promote shared decision-making for prostate cancer screening among Black male patients and their providers.
-
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
-
Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases.
-
Re: the economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data.
-
Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis.
-
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
-
Reassessing the diagnostic yield of saturation biopsy of the prostate.
-
Reduced Core Targeted (RCT) biopsy: Combining multiparametric magnetic resonance imaging - transrectal ultrasound fusion targeted biopsy with laterally-directed sextant biopsies - An alternative template for prostate fusion biopsy.
-
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
-
Reference ranges for serum prostate-specific antigen in black and white men without cancer.
-
Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma.
-
Reply: To PMID 25432832.
-
Report from Durham.
-
Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications.
-
Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline CHEK2 mutation.
-
Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy.
-
Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).
-
Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis.
-
Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer.
-
Rising PSA Level in an Anxious Postprostatectomy Patient.
-
Rising PSA after local therapy failure: immediate vs deferred treatment.
-
Rising PSA in nonmetastatic prostate cancer.
-
Rising prostate-specific antigen after primary prostate cancer therapy.
-
Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?
-
Role of 18
F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR
Expert Panel Narrative Review.
-
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
-
Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study.
-
Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?
-
Salvage radiation in men after prostate-specific antigen failure and the risk of death.
-
Salvage radiotherapy for rising or persistent PSA after radical prostatectomy.
-
Sample size calculations for evaluating a diagnostic test when the gold standard is missing at random.
-
Screening for prostate cancer in African Americans.
-
Screening for prostate cancer in high risk populations.
-
Screening for prostate cancer utilizing the prostate-specific antigen (PSA).
-
Secondary screening tests for prostate cancer: is more information better? Which test is best?
-
Section Editor's Notebook: Prostate Cancer Theranosis in Clinical Practice and in Clinical Trials-68
Ga-Prostate-Specific Member Antigen (PSMA)-11 PET/CT and 177
Lu-PSMA-617 Therapy.
-
Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.
-
Self-Assembling Peptide Gels for 3D Prostate Cancer Spheroid Culture.
-
Semiparametric Bayesian modeling of random genetic effects in family-based association studies.
-
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
-
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
-
Serum androgens: associations with prostate cancer risk and hair patterning.
-
Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.
-
Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database.
-
Serum metabolomic analysis of men on a low-carbohydrate diet for biochemically recurrent prostate cancer reveals the potential role of ketogenesis to slow tumor growth: a secondary analysis of the CAPS2 diet trial.
-
Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.
-
Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: a matched subset analysis.
-
Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology.
-
Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens.
-
Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen.
-
Simulation optimization of PSA-threshold based prostate cancer screening policies.
-
Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database.
-
Society of Behavior Medicine (SBM) Urges Congress to Ensure Affordable Care Act Coverage of Prostate Cancer Screening Support Services for High-Risk Men.
-
Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project.
-
Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial.
-
Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy.
-
Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer.
-
Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate-specific antigen levels.
-
Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs.
-
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
-
Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.
-
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
-
Surveillance after prostate focal therapy.
-
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.
-
Synergistic and tunable human gene activation by combinations of synthetic transcription factors.
-
Systematic biopsies: do they add prognostic information in men with clinically localized prostate cancer treated with radiation therapy alone?
-
Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.
-
Systemic therapy for prostate cancer.
-
TET2 binds the androgen receptor and loss is associated with prostate cancer.
-
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.
-
Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
-
The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.
-
The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.
-
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).
-
The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role?
-
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
-
The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration.
-
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
-
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.
-
The association between sexual function and prostate cancer risk in US veterans.
-
The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma.
-
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
-
The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer.
-
The effect of noise-cancelling headphones or music on pain perception and anxiety in men undergoing transrectal prostate biopsy.
-
The effect of pelvic radiation therapy on serum levels of prostate specific antigen.
-
The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
-
The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen.
-
The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
-
The experiences of unpartnered men with prostate cancer: a qualitative analysis.
-
The impact of PSA on prostate cancer management. Can we abandon routine staging pelvic lymphadenectomy?
-
The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer.
-
The influence of ejaculation on serum levels of prostate specific antigen.
-
The influence of statin medications on prostate-specific antigen levels.
-
The long-running disparity in early detection and treatment of prostate cancer in African American men.
-
The monomeric receptor binding domain of tetrameric α2-macroglobulin binds to cell surface GRP78 triggering equivalent activation of signaling cascades.
-
The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection.
-
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.
-
The role of androgen deprivation therapy combined with prostate brachytherapy.
-
The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL.
-
Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
-
Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.
-
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
-
To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence.
-
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
-
Treating the biochemical recurrence of prostate cancer after definitive primary therapy.
-
Treatment of PSA only recurrence of prostate cancer after prior local therapy.
-
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
-
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
-
Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate.
-
Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study.
-
Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence?
-
Twenty-five year evolution of medical hormonal therapy for prostate cancer.
-
Update on outcomes research databases in prostate cancer 2006.
-
Update on transrectal ultrasound-guided needle biopsy of the prostate.
-
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
-
Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
-
Use of prostate-specific antigen in black men: age-adjusted reference ranges for maximal cancer detection.
-
Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists.
-
Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients.
-
Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
-
Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.
-
Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.
-
Variables in predicting survival based on treating "PSA-only" relapse.
-
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
-
Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years.
-
What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation.
-
Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation.
-
p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.
-
Keywords of People
-
-
McDonnell, Donald Patrick,
Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine,
Cell Biology
-
Moorman, Patricia Gripka,
Professor Emeritus in Family Medicine and Community Health,
Duke Cancer Institute
-
Routh, Jonathan Charles,
Paul H. Sherman, M.D. Distinguished Associate Professor of Surgery,
Pediatrics